Peptide Schedule
Mazdutide32 residuesHQGTFTSDYSKYLDEKKAKEFVEWLLEGGSSGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Mazdutide
Benefits
About Mazdutide
Mazdutide is a dual-agonist peptide that activates both GLP-1 and glucagon receptors. The glucagon component adds thermogenic fat burning on top of GLP-1's appetite suppression. Available in high-concentration 100mg vials for extended protocols with less frequent vial changes. Clinical trials show significant weight loss with improvements in metabolic markers.
Who Should Consider Mazdutide
- Adults with BMI ≥28 (or ≥24 with weight-related comorbidity, per Chinese guidelines)
- Adults with type 2 diabetes inadequately controlled on metformin
- Individuals seeking dual-mechanism weight loss beyond GLP-1-only therapy
- Patients with obesity-related metabolic dysfunction (dyslipidemia, insulin resistance)
How Mazdutide Works
Mazdutide is an oxyntomodulin analogue that simultaneously activates GLP-1 and glucagon receptors. GLP-1 receptor activation suppresses appetite through hypothalamic signaling, slows gastric emptying to prolong satiety, and enhances glucose-dependent insulin secretion. Glucagon receptor activation increases hepatic energy expenditure and promotes fat oxidation, adding a thermogenic component that GLP-1-only drugs lack. This dual mechanism targets both sides of the energy balance equation — reduced intake and increased expenditure.
What to Expect
Titration initiation. Mild appetite suppression begins. GI side effects (nausea, diarrhea, decreased appetite) are most common in this phase as the body adjusts to dual-receptor activation.
Appetite suppression strengthens. Early weight loss of 3-5% is typical. GI side effects begin to ease for most users as dose escalates to 6mg.
Steady weight loss continues. Blood glucose and lipid markers start improving. Most users experience 6-10% body weight reduction during this window.
Escalation to full 9mg dose. Weight loss accelerates with the added thermogenic effect of glucagon activation. Phase 3 trials showed ~15% mean body weight loss by week 24.
Full dose maintenance. GLORY-2 trial data showed up to 20.1% body weight loss at 48 weeks. Metabolic markers continue improving. Weight loss rate plateaus as a new equilibrium is established.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 3mg | Weekly |
| Moderate | 6mg | Weekly |
| Aggressive | 9mg | Weekly |
Note: Dual GLP-1/glucagon agonist. Titrate from 3mg weekly. Long-acting formula in high-concentration vials. Developed by Innovent Biologics.
How to Inject Mazdutide
Inject subcutaneously once weekly. Rotate injection sites between abdomen, thigh, and upper arm. Begin at 3mg weekly and titrate upward every 4 weeks (3mg → 6mg → 9mg) to reduce GI side effects. Administer at the same time each week.
Pharmacokinetics
Source: Phase 1b trial (NCT04440345), ~7 days
Loading the interactive decay curve.
Side Effects
Nausea, vomiting, diarrhea (common during titration). Decreased appetite. Injection site reactions.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Known hypersensitivity to mazdutide or any excipients
- Severe gastrointestinal disease (e.g., gastroparesis)
Drug Interactions
- Insulin and sulfonylureas — increased hypoglycemia risk due to combined glucose-lowering effects
- Oral medications may have delayed absorption due to slowed gastric emptying
- Levothyroxine — monitor thyroid levels as absorption timing may be altered
- Warfarin — monitor INR more frequently during initiation and dose changes
Storage & Stability
Molecular Profile
Related Peptides
References
- Phase 2 RCT of Mazdutide in Chinese Overweight/Obese Adults (Nature Communications 2023)PubMed 38092790
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes — Phase 2 Trial (Diabetes Care 2024)PubMed 37943529
- Safety and Efficacy of Mazdutide (IBI362) 9mg and 10mg in Chinese Adults — Phase 1b Trial (eClinicalMedicine 2022)PubMed 36247927
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — GLORY-1 Phase 3 (NEJM 2025)PubMed 40421736